Palmitoyl Tripeptide-5 (SYN-COLL) (CAS 623172-55-4) is supplied by TCS NEXUS S.L. (Valencia, Spain) for European cosmetic formulators, brand R&D teams and B2B buyers reviewing matrix-care, firming-positioned and TGF-β pathway lipopeptide applications. The palmitoyl fatty acid conjugated to the Lys-Val-Lys (KVK) tripeptide sequence provides lipophilicity for stratum corneum penetration, delivering a thrombospondin-1 (TSP-1) mimetic motif to dermal fibroblasts at evaluation concentrations of 0.5–3.0% in emulsions and serum systems.
> Technical Specifications
| Product Name | Palmitoyl Tripeptide-5 |
|---|---|
| Molecular Structure |  |
| CAS Number | 623172-55-4 |
| Alias / Common Name | SYN-COLL; Palmitoyl Tripeptide-5; Pal-KVK; Palmitoyl-Lysyl-Valyl-Lysine |
| Molecular Formula | C33H65N5O5 |
| Molecular Weight | 611.9 g/mol |
| INCI Name | Palmitoyl Tripeptide-5 |
| Peptide Sequence | Pal-Lys-Val-Lys (KVK) — TSP-1 mimetic matrix-signalling lipopeptide |
| Purity / Assay | ≥98% (HPLC); confirm by batch COA |
| Appearance | White to off-white powder |
| Solubility / Handling | Limited direct water solubility due to palmitoyl chain; pre-dissolve in propylene glycol, butylene glycol or ethanol before incorporation into the aqueous phase or emulsion |
| pH Stability | Stable across pH 4.5–7.0; evaluate in the target leave-on emulsion or serum base; confirm pH after addition |
| Storage | Store sealed in cool, dry conditions protected from direct light; follow batch COA and SDS |
> Mechanism & Positioning
Palmitoyl Tripeptide-5 delivers the KVK (Lys-Val-Lys) tripeptide sequence to the dermis via palmitoyl-mediated skin penetration. Published Palmitoyl Tripeptide-5 literature discusses that the KVK motif mimics a key sequence from thrombospondin-1 (TSP-1) — a glycoprotein that activates latent TGF-β1 by displacing the latency-associated protein (LAP) from the TGF-β1 complex. Cell-based studies document activation of TGF-β1 signalling in dermal fibroblast models following treatment with Palmitoyl Tripeptide-5, with associated upregulation of collagen type I and extracellular matrix components discussed in fibroblast model assays. Fibroblast model data also notes that the TSP-1 mimetic mechanism positions Palmitoyl Tripeptide-5 as a direct TGF-β1 activator at the latent complex level — distinct from KTTKS-type peptides that engage β1-integrin/fibronectin receptor pathways to trigger indirect TGF-β agonism.
Based on available in vitro fibroblast data, Palmitoyl Tripeptide-5 is positioned for matrix-care serum, firming emulsion and multi-lipopeptide blend applications. The direct latent TGF-β1 activation mechanism differentiates Palmitoyl Tripeptide-5 from Matrixyl (Palmitoyl Pentapeptide-4/3) (fibronectin-receptor → indirect TGF-β), copper-delivery actives such as GHK-Cu (Copper Tripeptide-1) (LOX pathway), and neuromuscular actives such as Argireline (SNARE complex), enabling genuinely complementary pathway positioning in premium multi-peptide architecture.
> Application Concepts
Emulsion and Firming Cream Architecture
Palmitoyl Tripeptide-5 integrates into O/W and W/O emulsions at 0.5–3.0% in a glycol pre-mix. Pre-dissolve the powder in propylene glycol or butylene glycol (1:2 to 1:5 weight ratio, 40–50°C) before cool-down addition to the emulsion phase. The firming-positioned KVK-TGF-β1 mechanism is complemented in cream architecture by co-formulants targeting structural matrix repair: Palmitoyl Tripeptide-1 (Pal-GHK, fibronectin–collagen I receptor axis) and Matrixyl (Palmitoyl Pentapeptide-4/3) (β1-integrin TGF-β signalling). Confirm combined glycol pre-mix solubility and stability when including multiple lipopeptides before committing to manufacturing scale.
Serum and Lipopeptide Concentrate Architecture
In aqueous serum concentrates, pre-dissolve Palmitoyl Tripeptide-5 in a minimal volume of butylene glycol at 40–50°C, then introduce during cool-down below 40°C. The KVK sequence is stable across pH 4.5–7.0 and compatible with typical serum humectants, film formers and preservative systems. For multi-pathway matrix-care positioning in a concentrated serum format, Palmitoyl Tripeptide-5 (TSP-1 mimicry / TGF-β1 activation) may be evaluated alongside Matrixyl (Palmitoyl Pentapeptide-4/3) (fibronectin-receptor / indirect TGF-β) and GHK-Cu (Copper Tripeptide-1) (LOX crosslinking support) as a three-mechanism matrix-care concentrate targeting synthesis, crosslinking and signalling in parallel.
Multi-Lipopeptide Matrix-Care Positioning
Palmitoyl Tripeptide-5 is most impactful in multi-lipopeptide blends where each active operates via a distinct mechanism. Alongside Palmitoyl Tripeptide-5, formulators evaluate: Palmitoyl Tetrapeptide-7 (IL-6 modulation, calming cytokine regulation); Palmitoyl Tripeptide-1 (fibronectin–collagen I receptor targeting); and Matrixyl (fibronectin-receptor β1-integrin / TGF-β agonism). This mechanistic breadth supports broad matrix-care positioning claims framed around extracellular matrix synthesis and structural support. Each lipopeptide requires the same glycol pre-dissolution approach — a combined pre-mix preparation must be confirmed for solubility, clarity and assay retention before scale-up.
> Handling & Formulation Notes
Palmitoyl Tripeptide-5 does not dissolve directly in cold water at typical cosmetic use concentrations. Pre-dissolve in propylene glycol or butylene glycol (2–5 parts per part peptide) at 40–50°C with gentle stirring until clear. Introduce the resulting concentrate into the formulation during cool-down below 40°C; avoid prolonged exposure above 50°C to prevent palmitoyl ester degradation.
Maintain formulation pH within 4.5–7.0 after incorporating all actives and buffering agents. Evaluate interaction with anionic polymers (carbomers, xanthan) in the glycol pre-mix system at manufacturing scale. Confirm colour, clarity, assay retention and preservative efficacy via accelerated stability testing before scale-up. When combining multiple lipopeptides in a glycol pre-mix, verify that the combined weight-percent in the carrier does not exceed solubility limits — clouding at ambient temperature indicates re-dissolution issues that may affect the final formula.
> Supply & Documentation
Palmitoyl Tripeptide-5 (SYN-COLL) (CAS 623172-55-4) is available from TCS NEXUS S.L. (Valencia, Spain) for B2B cosmetic raw material projects. Standard documentation: COA, TDS, SDS. Sample and bulk quantities are discussed on a per-project basis; contact info@tcspeptides.com to initiate a sourcing review.
TCS NEXUS S.L. supports procurement and formulation teams in Germany, France, Italy, Spain, the United Kingdom, the Netherlands, Belgium, Poland, Sweden and Portugal, as well as international buyers in the United States, Canada, Japan, South Korea, Australia and New Zealand.
> Packaging & Storage
Palmitoyl Tripeptide-5 is supplied in sealed aluminium foil bags or bulk containers. Minimum quantities and packaging configurations are confirmed per order. Store below 25°C in a cool, dry location protected from light and moisture. Follow batch COA and SDS for specific storage and handling conditions.
> FAQ
What is Palmitoyl Tripeptide-5 (SYN-COLL)?
Palmitoyl Tripeptide-5 (SYN-COLL) (CAS 623172-55-4) is a palmitoylated tripeptide raw material consisting of the KVK sequence (Lys-Val-Lys) — a thrombospondin-1 (TSP-1) mimetic motif — conjugated to a palmitic acid chain for skin penetration. TCS NEXUS S.L. (Valencia, Spain) supplies Palmitoyl Tripeptide-5 (SYN-COLL) as a B2B cosmetic ingredient for matrix-care, firming and multi-lipopeptide blend applications.
What is the CAS number for Palmitoyl Tripeptide-5 and what is SYN-COLL?
The CAS number for Palmitoyl Tripeptide-5 is 623172-55-4. SYN-COLL is a trade name previously used in the cosmetic ingredient market for Pal-KVK peptide products with this CAS. Both terms refer to the same INCI-named Palmitoyl Tripeptide-5 (Pal-Lys-Val-Lys). For regulatory documentation and CPNP notification, use the INCI name Palmitoyl Tripeptide-5 and CAS 623172-55-4.
How does Palmitoyl Tripeptide-5 (SYN-COLL) boost collagen — what is the TSP-1 / TGF-β mechanism?
Palmitoyl Tripeptide-5 (SYN-COLL) carries the Lys-Val-Lys (KVK) sequence on a palmitoyl anchor and is a thrombospondin-1 (TSP-1) mimetic. It is described as activating latent TGF-β in the dermis, the growth factor that drives fibroblasts to synthesise new collagen — so it works by unlocking the skin’s own collagen-stimulating signal rather than supplying a structural fragment. The palmitoyl chain provides the lipophilicity needed for skin penetration.
How does Palmitoyl Tripeptide-5 differ from Matrixyl (Palmitoyl Pentapeptide-4/3)?
Palmitoyl Tripeptide-5 (KVK) activates latent TGF-β1 directly via TSP-1 mimicry at the latent complex level — displacing LAP to release active TGF-β1 in fibroblast models. Matrixyl (KTTKS, Palmitoyl Pentapeptide-4/3) acts via β1-integrin/fibronectin-receptor signalling, triggering indirect TGF-β agonism downstream. Both are TGF-β pathway actives, but via distinct receptor-interaction mechanisms — making them complementary rather than redundant in multi-lipopeptide matrix-care systems.
What use level of Palmitoyl Tripeptide-5 is typical, and how should it be evaluated?
Treat the use level as project-specific and establish it conservatively for your base and claim rather than to a fixed figure; it is commonly supplied as a diluted trade solution, so confirm whether you dose on a pure-peptide or trade-solution basis. We provide the pure material with COA — contact info@tcspeptides.com to align documentation.
Which actives pair with Palmitoyl Tripeptide-5 in a collagen-support system?
Because it activates TGF-β signalling, Palmitoyl Tripeptide-5 complements peptides that supply or organise matrix through other routes — Matrixyl (Palmitoyl Pentapeptide-4, procollagen matrikine), Palmitoyl Tripeptide-1 (Pal-GHK) and Decorinyl (fibril organisation) — plus niacinamide. As a lipopeptide it needs pre-dispersion; confirm clarity and pH in the finished base.
How should Palmitoyl Tripeptide-5 be pre-dissolved for formulation?
Pre-dissolve Palmitoyl Tripeptide-5 powder in propylene glycol or butylene glycol at a 1:2 to 1:5 weight ratio by warming to 40–50°C with gentle stirring until clear. Add this glycol concentrate to the water phase or emulsion during cool-down below 40°C. Direct addition of dry powder to cold water is not recommended. Confirm clarity of the pre-mix before incorporating into the batch. When combining multiple lipopeptides in a single glycol pre-mix, verify total solubility at ambient temperature before use.
What pH range keeps Palmitoyl Tripeptide-5 stable in an emulsion?
Palmitoyl Tripeptide-5 is most stable at roughly pH 4.5–7.0, matching serum and emulsion targets. Confirm the finished-product pH after all actives are incorporated and evaluate combined stability with low-pH actives such as ascorbic acid.
How should the lipopeptide Palmitoyl Tripeptide-5 be added during manufacturing?
Pre-disperse Palmitoyl Tripeptide-5 in propylene glycol or low-concentration ethanol before diluting into the aqueous or emulsion phase, then add during cool-down below 45°C. Confirm solution clarity and finished pH; standard emulsion cool-down protocols are compatible.
How should Palmitoyl Tripeptide-5 be stored?
Store Palmitoyl Tripeptide-5 sealed below 25°C in a cool, dry location protected from light and moisture. Follow specific storage and handling conditions stated in the SDS and batch COA. Once opened, reseal containers immediately and use within a period confirmed by stability data.
What documentation does TCS NEXUS S.L. provide for Palmitoyl Tripeptide-5?
TCS NEXUS S.L. provides standard B2B documentation for Palmitoyl Tripeptide-5 including COA (confirming CAS 623172-55-4, HPLC purity ≥98%), TDS (Technical Data Sheet) and SDS (Safety Data Sheet). Additional documentation such as specification sheets and INCI confirmation letters are available on a per-project basis. Contact info@tcspeptides.com to initiate a documentation and sourcing discussion.
What MOQ and sample options are available for Palmitoyl Tripeptide-5?
Sample and bulk quantities are confirmed on a per-project basis through TCS NEXUS S.L. Minimum order quantities depend on current stock, packaging configuration and project scope. R&D teams are encouraged to request samples for solubility, stability and compatibility evaluation before bulk planning. Contact info@tcspeptides.com with project scope and specification to begin a sourcing review.
Is Palmitoyl Tripeptide-5 (INCI) compliant with EU Cosmetics Regulation 1223/2009?
Palmitoyl Tripeptide-5 (INCI) is not listed as restricted, prohibited or regulated under EU Cosmetics Regulation 1223/2009 Annexes II–VI. The finished product manufacturer is responsible for CPSR and CPNP notification under EU Regulation 1223/2009. Use CAS 623172-55-4 and INCI name Palmitoyl Tripeptide-5 consistently in regulatory documentation; confirm purity and identity with the batch COA.
> Technical Support and Samples
Request COA documents, sample availability, or support for custom synthesis.